A randomized controlled trial depicted that Pregabalin is a better option than Amitriptyline for relieving pain in the treatment of excruciating diabetic neuropathy. Researchers compared the effects of Amitriptyline and Pregabalin for painful diabetic neuropathy management. Subjects were segregated into two groups at random.

A senior consultant who was blinded to the study's goal prescribed Amitriptyline at a dose of 25 mg once a day prior to bedtime for 6 weeks to group B and Pregabalin at a dose of 50 mg three times a day for 6 weeks to group A. Patients recorded their levels of pain on a Visual Analogue Scale (VAS) and a numerical score at the beginning and end of their therapy.

Overall, 100 patients were incorporated as per the inclusion requirements of the study. Subjects in group A received the prescribed amount of Pregabalin, whereas those in group B received Amitriptyline. The frequency and percentage of effect (pain relief) among Pregabalin and Amitriptyline to mitigate painful diabetic neuropathy was 27 (54.0) and 11 (22.0) respectively which was statistically significant.

Pregabalin is superior to Amitriptyline to ameliorate painful diabetic neuropathy. In the future, Pregabalin and Amitriptyline's effectiveness in treating diabetic peripheral neuropathy must be further investigated in various trials in order to develop management recommendations.